Jonathan Trent
Medical Oncology · Miami, FLNPI 1780770552
Payments from drug & device makers
Across 739 payments — averaging $8971.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$3.1M
- Servier Pharmaceuticals LLC$1.5M
- Servier Bioinnovation$536K
- Pfizer$444K
- Blueprint Medicines Corporation$370K
- Merck$262K
- plus $416K from 20 others
Across 3 payments — averaging $15,304 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$44K
- Servier Affaires Medicales$2K
What the payments were for
- Consulting fees$65,84664%
- Speaking & faculty fees$25,32925%
- Travel & lodging$7,5147%
- Food & beverage$3,4643%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 453 | $3,137,094 |
| Servier Pharmaceuticals LLC | 11 | $1,465,176 |
| Servier Bioinnovation | 17 | $535,548 |
| Pfizer | 9 | $443,505 |
| Blueprint Medicines Corporation | 32 | $369,861 |
| Merck | 16 | $262,138 |
| Daiichi Sankyo Inc. | 116 | $201,614 |
| Eli Lilly | 5 | $67,957 |
| Agios Pharmaceuticals, Inc. | 8 | $62,597 |
| Bayer | 34 | $55,419 |
| Boehringer Ingelheim | 5 | $9,138 |
| Novartis | 1 | $6,749 |
| Ipsen Biopharmaceuticals, Inc | 5 | $6,539 |
| Aadi Bioscience, Inc. | 8 | $4,383 |
| Springworks Therapeutics, Inc. | 2 | $1,089 |
| Exelixis Inc. | 1 | $172 |
| Tempus AI, Inc | 2 | $163 |
| GSK | 2 | $146 |
| Epizyme, Inc. | 1 | $85 |
| Amgen | 2 | $46 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
| Lilly USA, LLC | 1 | $39 |
| Seagen Inc. | 2 | $28 |
| Foundation Medicine, Inc. | 1 | $28 |
| AstraZeneca | 2 | $26 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,629,593 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 12 | $13,278 |
| Tramadol Hcl | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Leonel Hernandez AyaMiami$2.8M
- Craig MoskowitzMiami$2.7M
- Gilberto LopesMiami$2.4M
- Damian GreenMiami$2.1M
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.